Timothy Harrington’s Post

Clients often inquire about Medicare coverage for experimental procedures, particularly for conditions like cancer. Here’s some essential information: For unique medical conditions, clinical trials offer new, unapproved treatments. Medicare typically does not cover these experimental procedures. However, the costs are often covered by the pharmaceutical company or the entity developing the therapy. It’s crucial to stay informed and understand all your options. #Medicare #Employeebenefits #Medicarecoverage #HRInnovation #HRChallenges #HR #DoctorsChoiceusa #Healthcare

Our research initiative aimed to understand the current diagnostic tests, pharmaceutical interventions, and treatment modalities for Chronic Kidney Disease. Engaging Nephrologists, Urologists, and Laboratory Directors, we gathered invaluable feedback. These insights highlighted gaps and unmet needs in CKD management, guiding future advancements.     For research collaboration, email [email protected]   Visit www.idr.co to learn more about our projects.   #healthcareresearch #CKD #medicalInnovation #mrx #marketresearch #competitiveintelligence #research #consulting #expertnetwork

FDA granted ATEV of Humacyte a special advanced-therapy designation on Monday. Find out more. https://lnkd.in/dN-r94hs #humacyte #investing #fda #regulator #stockmarketnews #unitedstates #biotech #healthcare #pharmaceuticals #businessnews #heartdisease #foodanddrugadministration

In today's pharmaceutical landscape, understanding medical imaging trends and innovations is crucial. With MHN's panel, access a wealth of expertise to elevate your research strategies and gain actionable insights. Pharmaceutical brands and insight agencies, are you seeking in-depth insights in radiology? Look no further than MHN's specialized panel of radiologists. Whether exploring new pharmaceutical developments, testing marketing strategies, or understanding healthcare professionals' evolving needs, our radiology panel offers the depth and breadth of knowledge you need. Partner with us to harness the power of radiology insights for informed decision-making in your pharmaceutical endeavors. Discover a world of possibilities with MHN! Reach out today to start your journey towards success. #RadiologyInsights #PharmaResearch #MedicalImaging 🩺💊🧠

What is crucial for pharmaceutical companies to succeed with their clinical trials? Selected collection sites need to be audited in accordance to legal requierements.  Anke Löffler is responsible for the qualification of apheresis units for autologous lymphocyte collections to ensure compliance with GMP regulations.   She has already audited and supported more than 100 clinics and collection centers worldwide. Do you need support regarding the regulatory requirements that must be followed when dealing with human starting material? Get in touch with our Cellex experts. Your contact: [email protected] #startingmaterial #leukopaks #mobilizedleukopaks #wholeblood #bonemarrow #msc #celltherapy #genetherapy #research #healthydonormaterial #manufacturing #science #cdmo #ipsc 

The 4th Annual Psychedelic Therapeutics and Drug Development Conference has officially commenced! As a leader in helping bring psychedelic-assisted therapy to global health authorities for approval, we are hopeful that the discussions over the next 2 days bring forth new collaborations, ideas, and perspectives to a growing segment in the pharmaceutical industry. Don't miss our Regulatory Expert, Ritchie Patton’s session titled 'A Psychedelic Shift: Assessing the Potential for Nonmedical Use in a Changing Regulatory Landscape' on the first day at 4 PM! This session will dive deep into the challenges and nuances of evaluating nonmedical use potential for psychedelic drugs, highlighting the need for a refined regulatory approach. Expect insights into the FDA's requirements for abuse potential summaries and unique considerations for psychedelic therapeutics. For a deeper understanding of the evolving regulatory landscape and its implications, check out our latest blog: "Psychedelics and Regulatory Considerations Part II: A Shift in Lexicon and Implications of 'Nonmedical Use' on Labelling." 📖 Read more here: https://hubs.li/Q02yfjQQ0 #MDMA #Psychedelics #FDA #NewDrugApplication #PTSD #Neuroscience #DrugDevelopment #PsychedelicTherapeutics

UCB saw it's stock surging by 8.1%. They recently got approval to sell Bimzelx, a product against psorias, in the US and they can bring Zilbrysq on the market in Europe which helps adults with the neuromuscular disease generalized myasthenia gravis. Getting approval to bring medicine to market pharma companies need to meet a lot of requirements. The whole process can take 10-15 years. So if they can find ways to reduce this it can make a big difference. That's why companies like Clario, who provide technology-enabled clinical research services for pharmaceutical, biotech, and medical device companies, works with Dynatrace to accelerate clinical trials and reduce the time it takes to bring new medicine to the market. #pharma #medicine #observability

In today's pharmaceutical landscape, understanding medical imaging trends and innovations is crucial. With MHN's panel, access a wealth of expertise to elevate your research strategies and gain actionable insights. Pharmaceutical brands and insight agencies, are you seeking in-depth insights in radiology? Look no further than MHN's specialized panel of radiologists. Whether exploring new pharmaceutical developments, testing marketing strategies, or understanding healthcare professionals' evolving needs, our radiology panel offers the depth and breadth of knowledge you need. Partner with us to harness the power of radiology insights for informed decision-making in your pharmaceutical endeavors. Discover a world of possibilities with MHN! Reach out today to start your journey towards success. #RadiologyInsights #PharmaResearch #MedicalImaging 🩺💊🧠

Amylyx Pharmaceuticals' ALS drug, Relyvrio, didn't meet its goals in the crucial Phase III trial, casting uncertainty on its future. Despite this, the drug's safety profile remained consistent. Considerations - 🔹 The impact on ALS treatment advancements and patient hope. 🔹 Potential regulatory discussions and the commitment to patient well-being may guide Amylyx's next steps. This setback in ALS research emphasizes the challenges in neurodegenerative disease treatment but also the unwavering quest for solutions. #ALS #HealthcareNews #ClinicalTrials

In today's pharmaceutical landscape, understanding medical imaging trends and innovations is crucial. With MHN's panel, access a wealth of expertise to elevate your research strategies and gain actionable insights. Pharmaceutical brands and insight agencies, are you seeking in-depth insights in radiology? Look no further than MHN's specialized panel of radiologists. Whether exploring new pharmaceutical developments, testing marketing strategies, or understanding healthcare professionals' evolving needs, our radiology panel offers the depth and breadth of knowledge you need. Partner with us to harness the power of radiology insights for informed decision-making in your pharmaceutical endeavors. Discover a world of possibilities with MHN! Reach out today to start your journey towards success. #RadiologyInsights #PharmaResearch #MedicalImaging 🩺💊🧠